Vitamin D, chronic kidney disease and survival: A pluripotent hormone or just another bone drug?

Pediatric Nephrology

Volumn 26, Issue 1, 2011, Pages 7-18

  Biggar, Patrick H ^a   Liangos, Orfeas ^a   Fey, Holger ^a   Brandenburg, Vincent M ^b   Ketteler, Markus ^a  

^a KLINIKUM COBURG   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Calcidiol; Calcitriol; Cardiovascular; CKD MBD; Hyperparathyroidism; Mortality; Paricalcitol; Vitamin D

Indexed keywords

22 OXACALCITRIOL; CALCITRIOL; MULTIVITAMIN; PARATHYROID HORMONE; PARICALCITOL; PLACEBO; VITAMIN D; VITAMIN D RECEPTOR; DRUG DERIVATIVE;

ATHEROSCLEROSIS; AUTOIMMUNITY; BONE DISEASE; BONE METABOLISM; CALCIFICATION; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; HUMAN; HYPERPARATHYROIDISM; INFLAMMATION; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN INTAKE; ANIMAL; BONE MINERALIZATION; CHRONIC KIDNEY FAILURE; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANIMALS; CALCIFICATION, PHYSIOLOGIC; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; RENAL INSUFFICIENCY, CHRONIC; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 79952401459     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00467-010-1526-x     Document Type: Review

References (90)

1. Holick M (2007) Vitamin D deficiency. N Engl J Med 357:266-281
2. Lucas PA, Brown RC, Woodhead JS, Coles GA (1986) 1, 25- dihydroxycholecalciferol and parathyroid hormone in advanced chronic renal failure: effects of simultaneous protein and phosphorous restriction. Clin Nephrol 25:7-10 (Pubitemid 16187264)
3. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, Mallamaci F, Zoccali C (2009) Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 75:88-95
4. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS (1998) Hypovitaminosis D in medical inpatients. N Engl J Med 338:777-783 (Pubitemid 28135983)
5. Heaney RP, Dowell MS, Hale CA, Bendich A (2003) Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22:142-146 (Pubitemid 36417827)
6. Heaney RP (2008) Vitamin D in health and disease. Clin J Am Soc Nephrol 3:1535-1541
7. Holick MF, Biancuzzo RM, Chen TC, Klein EK, Young A, Bibuld D, Reitz R, Salameh W, Ameri A, Tannebaum AD (2008) Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab 93:677-681 (Pubitemid 351398538)
8. Armas LAG, Hollis BW, Heaney RP (2004) Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 89:5387-5391 (Pubitemid 39518413)
9. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, Andress DL (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71:31-38 (Pubitemid 44967731)
10. Tokmak F, Quack I, Schieren G, Sellin L, Rattensperger D, Holland-Letz T, Weiner SM, Rump LC (2008) High-dose cholecalciferol to correct vitamin D deficiency in haemodialysis patients. Nephrol Dial Transplant 23:4016-4020
11. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2008) Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Nephrol Dial Transplant 23:3670-3676
12. Mehrotra R, Kermah D, Budoff M, Salusky IB, Mao SS, Gao YL, Takasu J, Adler S, Norris K (2008) Hypovitaminosis D in chronic kidney disease. Clin J Am Soc Nephrol 3:1144-1151
13. Ozfirat Z, Chowdury TA (2010) Vitamin D deficiency and type 2 diabetes. Postgrad Med J 86:18-25
14. Menon S, Valentini RP, Hidalgo G, Peschansky L, Mattoo TK (2008) Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease. Pediatr Nephrol 23:1831-1836
15. Belostotsky V, Mughal MZ, Berry JL, Webb NJ (2008) Vitamin D deficiency in children with renal disease. Arch Dis Child 93:959-962
16. Seeherunvong W, Abitbol CL, Chandar J, Zilleruelo G, Freundlich M (2009) Vitamin D insufficiency and deficiency in children with early chronic kidney disease. J Pediatr 154:906-911.e1
17. Ali FN, Arguelles LM, Langman CB, Price HE (2009) Vitamin D deficiency in children with chronic kidney disease: uncovering an epidemic. Pediatrics 123:791-796
18. Prié D, Ureña Torres P, Friedlander G (2009) Latest findings in phosphate homeostasis. Kidney Int 75:882-889
19. Tomida K, Hamano T, Mikami S, Fujii N, Okada N, Matsui I, Nagasawa Y, Moriyama T, Ito T, Imai E, Isaka Y, Rakugi H (2009) Serum 25-hydroxyvitamin D as an independent determinant of 1-84 PTH and bone mineral density in non-diabetic predialysis CKD patients. Bone 44:678-683
20. Ritter CS, Armbrecht HJ, Slatopolsky E, Brown AJ (2006) 25-hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 70:654-659 (Pubitemid 44215339)
21. Clements MR, Davies M, Hayes ME, Hickey CD, Lumb GA, Mawer EB, Adams PH (1992) The role of 1, 25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol (Oxf) 37:17-27
22. Gallieni M, Kamimura S, Ahmed A, Bravo E, Delmez J, Slatopolsky E, Dusso A (1995) Kinetics of monocyte 1 alphahydroxylase in renal failure. Am J Physiol 268:F746-F753
23. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, Ochoa MT, Schauber J, Wu K, Meinken C, Kamen DL, Wagner M, Bals R, Steinmeyer A, Zügel U, Gallo RL, Eisenberg D, Hewison M, Hollis BW, Adams JS, Bloom BR, Modlin RL (2006) Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311:1770-1773
24. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16:713-716 (Pubitemid 40933586)
25. Segersten U, Correa P, Hewison M, Hellman P, Dralle H, Carling T, Akerström G, Westin G (2002) 25-hydroxyvitamin D(3)-1alphahydroxylase expression in normal and pathological parathyroid glands. J Clin Endocrinol Metab 87:2967-2972 (Pubitemid 34655371)
26. Autier P, Gandini S (2007) Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 167:1730-1737 (Pubitemid 47403059)
27. Dobnig H, Pilz S, Scharnagl H, Renner W, Seelhorst U, Wellnitz B, Kinkeldei J, Boehm BO, Weihrauch G, Maerz W (2008) Independent association of low serum 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 168:1340-1349 (Pubitemid 351930842)
28. Melamed ML, Michos ED, Post W, Astor B (2008) 25- hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 168:1629-1637
29. Wang TJ, Pencina MJ, Booth SL, Jacques PF, Ingelsson E, Lanier K, Benjamin EJ, D'Agostino RB,Wolf M, Vasan RS (2008) Vitamin D deficiency and risk of cardiovascular disease. Circulation 117:503-511
30. de Boer IH, Kestenbaum B, Shoben AB, Michos ED, Sarnak MJ, Siscovick DS (2009) 25-hydroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 20:1805-1812
31. Barreto DV, Barreto FC, Liabeuf S, Temmar M, Boitte F, Choukroun G, Fournier A, Massy ZA (2009) Vitamin D affects survival independently of vascular calcification in chronic kidney disease. Clin J Am Soc Nephrol 4:1128-1135
32. Wang AY, Lam CW, Sanderson JE, Wang M, Chan IH, Lui SF, Sea MM, Woo J (2008) Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study. Am J Clin Nutr 87:1631-1638 (Pubitemid 351872624)
33. Chapuy MC, Arlot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, Meunier PJ (1992) Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med 327:1637-1642
34. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997) Effect of calcium and vitamin D on bone density in men and women 65 years of age or older. N Engl J Med 337:670-676 (Pubitemid 27375473)
35. Bischoff-Ferrari HA, Giovannucci E, Willet WC, Dietrich T, Dawson-Hughes B (2006) Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 84:18-28 (Pubitemid 44699167)
36. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586-1591 (Pubitemid 46890428)
37. Chlebowski RT, Johnson KC, Kooperberg C, Pettinger M, Wactawski-Wende J, Rohan T, Rossouw J, Lane D, O'Sullivan MJ, Yasmeen S, Hiatt RA, Shikany JM, Vitolins M, Khandekar J, Hubbell FA, Women's Health Initiative Investigators (2008) Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst 100:1581-1591
38. Hsia J, Heiss G, Ren H, Allison M, Dolan NC, Greenland P, Heckbert SR, Johnson KC, Manson JE, Sidney S, Trevisan M, Women's Health Initiative Investigators (2007) Calcium/vitamin D supplementation and cardiovascular events. Circulation 115:846-854 (Pubitemid 46294725)
39. Shoji T, Shinohara K, Kimoto E, Emoto M, Tahara H, Koyama H, Inaba M, Fukumoto S, Ishimura E, Miki T, Tabata T, Nishizawa Y (2004) Lower risk for cardiovascular mortality in oral 1alphahydroxy vitamin D3 users in a haemodialysis population. Nephrol Dial Transplant 19:179-184 (Pubitemid 38072630)
40. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, Thadhani R (2005) Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 16:1115-1125 (Pubitemid 41710323)
41. National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42(4 Suppl 3):S1-201
42. Young EW, Albert JM, Satayathum S, Goodkin DA, Pisoni RL, Akiba T, Akizawa T, Kurokawa K, Bommer J, Piera L, Port FK (2005) Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study. Kidney Int 67:1179-1187 (Pubitemid 41623345)
43. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS,McAllister CJ, Budoff MJ, Salusky IB, Kopple JD (2006) Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 70:771-780 (Pubitemid 44215354)
44. Naves-Díaz M, Alvarez-Hernández D, Passlick-Deetjen J, Guinsburg A, Marelli C, Rodriguez-Puyol D, Cannata-Andía JB (2008) Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 74:1070-1078
45. Cozzolino M, Brandenburg V (2009) Paricalcitol and outcome: a manual on how a vitamin D receptor activator (VDRA) can help us to get down the üU". Clin Nephrol 71:593-601
46. Tentori F, Albert JM, Young EW, Blayney MJ, Robinson BM, Pisoni RL, Akiba T, Greenwood RN, Kimata N, Levin NW, Piera LM, Saran R, Wolfe RA, Port FK (2009) The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant 24:963-972
47. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF (2009) Vitamin D compounds for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev (4):CD005633
48. Palmer SC, McGregor DO, Craig JC, Elder G, Macaskill P, Strippoli GF (2009) Vitamin D compounds for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev (4):CD008175
49. Teng M, Wolf M, Lowrie E, Ofsthun N, Lazarus JM, Thadhani R (2003) Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 349:446-456 (Pubitemid 36910023)
50. Liu S, Quarles LD (2007) How fibroblast growth factor 23 works. J Am Soc Nephrol 18:1637-1647 (Pubitemid 46870300)
51. Stubbs JR, Liu S, Tang W, Zhou J, Wang Y, Yao X, Quarles LD (2007) Role of hyperphosphatemia and 1, 25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol 18:2116-2124 (Pubitemid 47041077)
52. Ohnishi M, Nakatani T, Lanske B, Razzaque MS (2009) Reversal of mineral ion homeostasis and soft-tissue calcification of Klotho knockout mice by deletion of vitamin D 1alpha-hydroxylase. Kidney Int 75:1166-1172
53. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M (2005) Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205-2215 (Pubitemid 41716454)
54. Urena Torres P, Friedlander G, de Vernejoul MC, Silve C, Prié D (2008) Bone mass does not correlate with the serum fibroblast growth factor 23 in hemodialysis patients. Kidney Int 73:102-107 (Pubitemid 350273643)
55. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M (2008) Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 359:584-592
56. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, Chazot C (2009) High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 24:2792-2796
57. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, deFilippi C, Wolf M (2009) Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 119:2545-2552
58. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE (2009) Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 207:546-551
59. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1, 25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 110:229-238 (Pubitemid 34787360)
60. Zhou C, Lu F, Cao K, Xu D, Goltzman D, Miao D (2008) Calcium-independent and 1, 25(OH)2D3-dependent regulation of the renin-angiotensin system in 1alpha-hydroxylase knockout mice. Kidney Int 74:170-179 (Pubitemid 351915078)
61. Fryer RM, Rakestraw PA, Nakane M, Dixon D, Banfor PN, Koch KA, Wu-Wong JR, Reinhart GA (2007) Differential inhibition of renin mRNA expression by paricalcitol and calcitriol in C57/BL6 mice. Nephron Physiol 106:76-81
62. Matthias S, Busch R, Merke J, Mall G, Thomasset M, Ritz E (1991) Effects of 1, 25(OH)2D3 on compensatory renal growth in the growing rat. Kidney Int 40:212-218
63. Makibayashi K, Tatematsu M, Hirata M, Fukushima N, Kusano K, Ohashi S, Abe H, Kuze K, Fukatsu A, Kita T, Doi T (2001) A vitamin D analog ameliorates glomerular injury on rat glomerulonephritis. Am J Pathol 158:1733-1741 (Pubitemid 32422938)
64. Zhang Z, Zhang Y, Ning G, Deb DK, Kong J, Li YC (2008) Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci USA 105:15896-15901
65. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B (2008) Suppression of reninangiotensin gene expression in the kidney by paricalcitol. Kidney Int 74:1394-1402
66. Tan X, Wen X, Liu Y (2008) Paricalcitol inhibits renal inflammation by promoting vitamin D receptor-mediated sequestration of NF-kappaB signaling. J Am Soc Nephrol 19:1741-1752
67. Matsui I, Hamano T, Tomida K, Inoue K, Takabatake Y, Nagasawa Y, Kawada N, Ito T, Kawachi H, Rakugi H, Imai E, Isaka Y (2009) Active vitamin D and its analogue, 22-oxacalcitriol, ameliorate puromycin aminonucleoside-induced nephrosis in rats. Nephrol Dial Transplant 24:2354-2361
68. Xiao H, Shi W, Liu S, Wang W, Zhang B, Zhang Y, Xu L, Liang X, Liang Y (2009) 1, 25-Dihydroxyvitamin D(3) prevents puromycin aminonucleoside-induced apoptosis of glomerular podocytes by activating the phosphatidylinositol 3-kinase/ Akt-signaling pathway. Am J Nephrol 30:34-43
69. Resnick LM, Müller FB, Laragh JH (1986) Calciumregulating hormones in essential hypertension. Relation to plasma renin activity and sodium metabolism Ann Intern Med 105:649-654 (Pubitemid 17176965)
70. Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D (2005) Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68:2823-2828 (Pubitemid 43251029)
71. Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N (2009) Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 54:647-652
72. Xiang W, Kong J, Chen S, Cao LP, Qiao G, Zheng W, Liu W, Li X, Gardner DG, Li YC (2005) Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 288:E125-E132 (Pubitemid 40023798)
73. Bodyak N, Ayus JC, Achinger S, Shivalingappa V, Ke Q, Chen YS, Rigor DL, Stillman I, Tamez H, Kroeger PE, Wu-Wong RR, Karumanchi SA, Thadhani R, Kang PM (2007) Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci USA 104:16810-16815 (Pubitemid 350210947)
74. Repo JM, Rantala IS, Honkanen TT, Mustonen JT, Kööbi P, Tahvanainen AM, Niemelä OJ, Tikkanen I, Rysä JM, Ruskoaho HJ, Pörsti IH (2007) Paricalcitol aggravates perivascular fibrosis in rats with renal insufficiency and low calcitriol. Kidney Int 72:977-984 (Pubitemid 47530574)
75. Tishkoff DX, Nibbelink KA, Holmberg KH, Dandu L, Simpson RU (2008) Functional vitamin D receptor (VDR) in the t-tubules of cardiac myocytes: VDR knockout cardiomyocyte contractility. Endocrinology 149:558-564 (Pubitemid 351159356)
76. Price PA, Omid N, Than TN, Williamson MK (2002) The amino bisphosphonate ibandronate prevents calciphylaxis in the rat at doses that inhibit bone resorption. Calcif Tissue Int 71:356-363 (Pubitemid 36929618)
77. Haffner D, Hocher B, Müller D, Simon K, König K, Richter CM, Eggert B, Schwarz J, Godes M, Nissel R, Querfeld U (2005) Systemic cardiovascular disease in uremic rats induced by 1, 25 (OH)2D3. J Hypertens 23:1067-1075 (Pubitemid 40637927)
78. Mizobuchi M, Finch JL, Martin DR, Slatopolsky E (2007) Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int 72:709-715 (Pubitemid 47373790)
79. Lopez I,Mendoza FJ, Aguilera-Tejero E, Perez J, Guerrero F,Martin D, Rodriguez M (2008) The effect of calcitriol, paricalcitol, and a calcimimetic on extraosseous calcifications in uremic rats.Kidney Int 73:300-307
80. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA (2008) Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol 19:1509-1519
81. Cardús A, Panizo S, Parisi E, Fernandez E, Valdivielso JM (2007) Differential effects of vitamin D analogs on vascular calcification. J Bone Miner Res 22:860-866 (Pubitemid 351339746)
82. Stenvinkel P, Ketteler M, Johnson RJ, Lindholm B, Pecoits-Filho R, Riella M, Heimbürger O, Cederholm T, Girndt M (2005) IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia-the good, the bad, and the ugly. Kidney Int 67:1216-1233 (Pubitemid 40463099)
83. Zimmermann J, Herrlinger S, Pruy A, Metzger T, Wanner C (1999) Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int 55:648-658 (Pubitemid 29082891)
84. Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B (2006) Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD. Am J Kidney Dis 47:139-148 (Pubitemid 41828276)
85. Cutolo M, Otsa K, Uprus M, Paolino S, Seriolo B (2007) Vitamin D in rheumatoid arthritis. Autoimmun Rev 7:59-64 (Pubitemid 47633393)
86. Deluca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. FASEB J 15:2579-2585 (Pubitemid 33131084)
87. de Abreu DA, Babron MC, Rebeix C, Fontenille J, Yaouanq D, Brassat B, Fontaine F, Clerget-Darpoux F, Jehan F, Feron F (2009) Season of birth and not vitamin D receptor promoter polymorphisms is a risk factor for multiple sclerosis. Mult Scler 15:1146-1152
88. Lewy H, Rotstein A, Kahana E, Marrosu MG, Cocco E, Laron Z (2008) Juvenile multiple sclerosis similar to type I diabetes mellitus has a seasonality of month of birth which differs from that in the general population. J Pediatr Endocrinol Metab 21:473-437
89. Garland CF, Gorham ED, Mohr SB, Garland FC (2009) Vitamin D for cancer prevention: global perspective. Ann Epidemiol 19:468-483
90. Grant WB, Holick MF (2005) Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev 10:94-111 (Pubitemid 40911119)